A detailed history of Smith Anglin Financial, LLC transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Smith Anglin Financial, LLC holds 12,000 shares of CGTX stock, worth $7,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,000
Previous 12,000 -0.0%
Holding current value
$7,440
Previous $19,000 73.68%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 17, 2024

BUY
$0.96 - $2.42 $11,520 - $29,040
12,000 New
12,000 $22,000

Others Institutions Holding CGTX

About COGNITION THERAPEUTICS INC


  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $14.1M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Smith Anglin Financial, LLC Portfolio

Follow Smith Anglin Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Anglin Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Anglin Financial, LLC with notifications on news.